Evidence mapPaperPMID 41009493Full record

ReviewInternational journal of molecular sciences2025

Boosting Neurogenesis as a Strategy in Treating Alzheimer's Disease.

Abena Dwamena, Rashini Beragama-Arachchi, Hongmin Wang

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Abena DwamenaDepartment of Pharmacology and Neuroscience, Garrison Institute on Aging, Center of Excellence for Translational Neuroscience and Therapeutics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
Rashini Beragama-ArachchiDepartment of Pharmacology and Neuroscience, Garrison Institute on Aging, Center of Excellence for Translational Neuroscience and Therapeutics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.ORCID 0000-0001-6476-2395
Hongmin WangDepartment of Pharmacology and Neuroscience, Garrison Institute on Aging, Center of Excellence for Translational Neuroscience and Therapeutics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.ORCID 0000-0002-0392-4458

Funding

NIA NIH HHS RF1 AG072510NIH/NIA AG072510
6 · The paper itself

Abstract

Alzheimer's disease (AD) causes progressive cognitive decline and neuronal loss, partly due to the buildup of amyloid-β (Aβ) plaques and tau tangles. Despite years of research, treatments targeting these hallmark pathologies have yielded only modest clinical success, prompting interest in regenerative approaches to restore the brain's ability to repair itself. One such approach focuses on adult hippocampal neurogenesis, the process by which neural stem cells (NSCs) produce new neurons throughout life. In AD, this process is impaired, worsening cognitive deficits. In this review, we examine the molecular pathways that control adult neurogenesis, including transcriptional, epigenetic, inflammatory, and metabolic mechanisms, and how they become dysregulated in AD. We also highlight various therapeutic strategies aimed at boosting neurogenesis, such as pharmacological treatments, stem cell therapy, gene therapy, and epigenetic modulation. Preclinical studies indicate that enhancing neurogenesis can improve cognition and reduce brain pathology in AD models. Several of these treatments are now being tested in clinical trials. Ultimately, promoting neurogenesis may offer a promising avenue to complement current AD therapies and help restore lost neural function.

Indexed as

Alzheimer DiseaseNeurogenesisAnimalsEpigenesis, GeneticGenetic TherapyHumansNeural Stem Cellsadult hippocampal neurogenesisAlzheimer’s diseasecognitive declinedementia treatmentepigenetic regulationneural stem cellsneurogenesis enhancementneurotrophic factorsregenerative therapystem-cell therapy

Identifiers

PMID41009493
PMCPMC12470200

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.